Axsome Therapeutics (AXSM) Tops Q1 EPS by $1.03; Offers Operational Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Needham sees mature node semiconductor strength in latest tracker
Axsome Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update
May 8, 2023 7:00 AM EDTAuvelity® 1Q 2023 net product sales of $15.7 million
Total 1Q 2023 net product sales of $28.6 million
Total 1Q 2023 revenue of $94.6 million, including Sunosi® ex-U.S. license agreement upfront payment
Company to host conference call today at 8:00 AM Eastern
NEW YORK, May 08, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today reported... More
